Translational Neurodegeneration (Jan 2024)

The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases

  • Arazu Sharif,
  • John Mamo,
  • Virginie Lam,
  • Hani Al-Salami,
  • Armin Mooranian,
  • Gerald F. Watts,
  • Roger Clarnette,
  • Giuseppe Luna,
  • Ryu Takechi

DOI
https://doi.org/10.1186/s40035-024-00398-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Neurodegenerative disorders present complex pathologies characterized by various interconnected factors, including the aggregation of misfolded proteins, oxidative stress, neuroinflammation and compromised blood–brain barrier (BBB) integrity. Addressing such multifaceted pathways necessitates the development of multi-target therapeutic strategies. Emerging research indicates that probucol, a historic lipid-lowering medication, offers substantial potential in the realm of neurodegenerative disease prevention and treatment. Preclinical investigations have unveiled multifaceted cellular effects of probucol, showcasing its remarkable antioxidative and anti-inflammatory properties, its ability to fortify the BBB and its direct influence on neural preservation and adaptability. These diverse effects collectively translate into enhancements in both motor and cognitive functions. This review provides a comprehensive overview of recent findings highlighting the efficacy of probucol and probucol-related compounds in the context of various neurodegenerative conditions, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and cognitive impairment associated with diabetes.

Keywords